Medigen Vaccine Biologics Cash Flow Conversion Efficiency
Medigen Vaccine Biologics cash flow conversion efficiency. Based on the latest financial reports, Medigen Vaccine Biologics (6547) has a cash flow conversion efficiency ratio of -0.026x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-91.20 Million ≈ $-2.87 Million USD) by net assets (NT$3.56 Billion ≈ $112.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medigen Vaccine Biologics (2012–2025)
Cash flow conversion efficiency of Medigen Vaccine Biologics from 2012 to 2025. This chart illustrates how Medigen Vaccine Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 6547 stock price for real-time trading data and today's change.
Medigen Vaccine Biologics Cash Flow Conversion Ratio Explained
Medigen Vaccine Biologics cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medigen Vaccine Biologics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigen Vaccine Biologics ranked by their cash flow conversion efficiency. Also see market cap of Medigen Vaccine Biologics for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Keck Seng Malaysia Bhd
KLSE:3476
|
0.010x |
|
Jinxiandai Information Industry Co
SHE:300830
|
0.013x |
|
Salmones Camanchaca S.A
SN:SALMOCAM
|
-0.019x |
|
Community Healthcare Trust Inc
NYSE:CHCT
|
0.042x |
|
Energisa Mato Grosso - Distribuidora de Energia S/A
SA:ENMT3
|
-0.074x |
|
Caleres Inc
NYSE:CAL
|
0.123x |
|
High Liner Foods Incorporated
TO:HLF
|
-0.007x |
|
Chongqing Yukaifa Co Ltd
SHE:000514
|
0.003x |
Annual Cash Flow Conversion Efficiency for Medigen Vaccine Biologics (2012–2025)
The table below shows the annual cash flow conversion efficiency of Medigen Vaccine Biologics from 2012 to 2025. Review 6547 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$3.48 Billion ≈ $109.62 Million |
NT$-49.09 Million ≈ $-1.55 Million |
-0.014x | -233.28% |
| 2024-12-31 | NT$3.85 Billion ≈ $121.30 Million |
NT$40.75 Million ≈ $1.28 Million |
0.011x | +108.52% |
| 2023-12-31 | NT$3.85 Billion ≈ $121.19 Million |
NT$-477.75 Million ≈ $-15.05 Million |
-0.124x | +43.27% |
| 2022-12-31 | NT$5.03 Billion ≈ $158.44 Million |
NT$-1.10 Billion ≈ $-34.69 Million |
-0.219x | -276.53% |
| 2021-12-31 | NT$4.68 Billion ≈ $147.32 Million |
NT$579.89 Million ≈ $18.27 Million |
0.124x | +166.03% |
| 2020-12-31 | NT$3.14 Billion ≈ $98.97 Million |
NT$-589.97 Million ≈ $-18.59 Million |
-0.188x | +44.52% |
| 2019-12-31 | NT$1.37 Billion ≈ $43.06 Million |
NT$-462.65 Million ≈ $-14.58 Million |
-0.338x | -53.14% |
| 2018-12-31 | NT$1.61 Billion ≈ $50.79 Million |
NT$-356.33 Million ≈ $-11.23 Million |
-0.221x | -54.92% |
| 2017-12-31 | NT$1.52 Billion ≈ $47.92 Million |
NT$-217.03 Million ≈ $-6.84 Million |
-0.143x | -28.34% |
| 2016-12-31 | NT$1.47 Billion ≈ $46.30 Million |
NT$-163.37 Million ≈ $-5.15 Million |
-0.111x | -169.10% |
| 2015-12-31 | NT$1.34 Billion ≈ $42.35 Million |
NT$216.26 Million ≈ $6.81 Million |
0.161x | +133.76% |
| 2014-12-31 | NT$1.08 Billion ≈ $33.99 Million |
NT$-513.98 Million ≈ $-16.19 Million |
-0.476x | -201.54% |
| 2013-12-31 | NT$457.94 Million ≈ $14.43 Million |
NT$-72.36 Million ≈ $-2.28 Million |
-0.158x | -269.62% |
| 2012-12-31 | NT$128.00 Million ≈ $4.03 Million |
NT$-5.47 Million ≈ $-172.40K |
-0.043x | -- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more